Conjugate polysaccharide vaccine
Updated · Methodology
First line
PCV20 during breastfeeding. Per CDC ACIP 2024 and SEPAR 2023, recommended for adults ≥50, immunocompromise, chronic heart/lung/liver disease, diabetes. Breastfeeding is not a contraindication.
Sources
ICD-10: Z23 · ICD-11: QC00
Contains capsular polysaccharides from 20 pneumococcal serotypes conjugated to CRM197 carrier protein. Conjugation produces T-cell-dependent immune response with memory, unlike polysaccharide-only PPSV23. Covers main invasive serotypes. Adjuvant – aluminum phosphate.
Use when indicated.
Fully compatible. Hale L1.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Pneumococcal conjugate vaccine PCV20 is evaluated for the following indications with varying evidence strength: Vaccination during breastfeeding (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Pneumococcal conjugate vaccine PCV20 (≥ 1 in 100): Injection-site pain, Fatigue, Myalgia. See the Safety section for uncommon and serious reactions.
Use when indicated.
Fully compatible. Hale L1.
Pneumococcal conjugate vaccine PCV20 is contraindicated in: Anaphylaxis to components or CRM197. Full list in the Safety section.
RSV vaccine, recombinant (maternal), Tdap – tetanus, diphtheria, acellular pertussis vaccine, COVID-19 vaccine, mRNA (Moderna), COVID-19 vaccine, mRNA (Pfizer-BioNTech), Hepatitis B vaccine, recombinant, Inactivated influenza vaccine, Hepatitis A vaccine, inactivated, HPV vaccine, nonavalent